Facebook
X
LinkedIn
ForwardAdvancing Obesity Care: Leveraging Evidence-Based Medicine and Shared Decision-Making for Effective Weight Management
Through this course, you will learn how to screen for obesity and obesity-related complications, implement evidence-based obesity intervention plans, tailor treatments for high-risk patients, and incorporate shared decision-making strategies to deliver personalized treatment plans.
This activity will help you:
- Provide early intervention before obesity-related complications develop
- Expand your toolkit to incorporate GLP-1 medications in addition to other, non-pharmacologic interventions.
- Create personalized, evidence-based long-term care plans
- Address health equity gaps
The Advancing Obesity Care course uses a microlearning format, offering three 20-minute modules that deliver high-impact, practical content. You will gain insights on how to effectively manage patients using novel, highly effective obesity medications and to apply shared decision-making techniques to improve patient engagement and long-term adherence.
Target Audience
The intended audience is U.S.-based primary care and geriatric clinicians who treat adults. This includes internal medicine (IM) and family medicine (FM) physicians and residents as well as nurse practitioners (NPs) and physician associates (PAs).
Learning Objectives
Activity 1: Diagnosis and Health Equity of Obesity Diagnosis
- Demonstrate proficiency in the diagnosis and evidence-based management of obesity in clinical practice.
- Apply strategies to recognize and reduce weight stigma and bias, and to prioritize obesity as a key health concern in diverse patient populations.
- Identify and address disparities in obesity care, with particular attention to improving access and outcomes in underserved communities.
Activity 2: Shared Decision-Making Strategies
- Demonstrate how to improve patient outcomes using case-based discussion and evidence-based strategies.
- Review critical elements of the diagnosis, evaluation and referrals in patients with obesity.
- Utilize shared decision-making strategies to engage patients in selecting personalized, evidence-based obesity treatments, and improve patient outcomes through comprehensive obesity care.
Activity 3: Obesity Management and Outcomes
- Incorporate the latest clinical evidence and FDA-approved therapies into individualized obesity management.
- Recognize how effective obesity treatment improves outcomes in chronic conditions such as diabetes, cardiovascular disease, heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea (OSA), and metabolic dysfunction–associated steatohepatitis (MASH).
- Discuss emerging and next-generation incretin therapies and their potential to expand treatment access and durability.
Format & Estimated Time to Complete: This activity features 1.00 hour of videos, resources, exams, and an evaluation.
Disclosure of Support: This activity is supported by an independent education grant from Eli Lilly and Novo Nordisk.
Exam/Assessment: A score of 100% is required to receive AMA PRA Category 1 Credits™.
Disclosure Statement:
All individuals in control of the content for a Massachusetts Medical Society accredited continuing education activity must disclose all financial relationships with ineligible companies within the past 24 months. The following individuals disclosed relevant relationships with ineligible companies.
All relevant financial relationships have been mitigated prior to the beginning of this activity in accordance with ACCME and MMS policies. For this activity, all other individuals in control of content did not disclose any relevant financial relationships with ineligible companies.
Activity Term:
Original Release Date: November 19, 2025
Review Date(s): N/A
Termination Date: November 18, 2026
Activity Director/Planner: Michael A. Weintraub, MD
Clinical Assistant Professor of Endocrinology, NYU Langone Medical Center
Dr. Michael Weintraub is a Clinical Assistant Professor of Medicine in the Division of Endocrinology at NYU Langone Medical Center. He is triple board certified in endocrinology, obesity medicine, and internal medicine. Michael completed his fellowship in Endocrinology, Diabetes and Metabolism, at New York Presbyterian Weill Cornell Medical Center. Michael earned his medical degree from Robert Wood Johnson Medical School and completed Internal Medicine Residency at Jefferson University Hospital. He can be found on X/Twitter @MWeintraubMD.
Speaker: Sean Wharton, MD, FRCPC, PharmD
Assistant Professor University of Toronto
Adjunct Professor McMaster University, York University,
Wharton Medical Clinic
Dr. Wharton has his doctorate in Pharmacy and Medicine from the University of Toronto in Canada. He practices internal medicine and is the director of the Wharton Medical Clinic, a community-based weight management and diabetes clinic. He is an assistant professor at the University of Toronto and adjunct professor at McMaster and York University. He is the lead author of the 2020 Canadian Obesity Guidelines, which has been recognized around the world and has published many peer-reviewed articles in international medical journals.
Dr. Wharton is involved in advocacy to achieve health equity in medicine.
Speaker: Tirissa J. Reid, MD, DABOM
Associate Professor of Medicine
Columbia University Vagelos College of Physicians & Surgeons
Dr. Tirissa J. Reid is an Associate Professor of Medicine at Columbia University Irving Medical Center in New York City and is board-certified in Endocrinology, Diabetes, and Metabolism and Obesity Medicine. She treats patients with obesity at the Metabolic and Weight Control Center at CUIMC, serves as a clinical medical educator and faculty for the Institute of Human Nutrition Master's program. She has done research on the topics of acromegaly, weight bias, and the resolution of comorbidities with weight loss.
Speaker: Jaime Almandoz, MD, MBA, DABOM, FTOS
Professor of Medicine, Division of Endocrinology
University of Texas Southwestern Medical Center
Dr. Jaime Almandoz is Professor of Internal Medicine and Medical Director of the Weight Wellness Obesity Medicine Program at UT Southwestern Medical Center. Board-certified in Endocrinology, Internal Medicine, and Obesity Medicine, he serves on the Board of Directors of the American Board of Obesity Medicine and holds leadership roles within the American Association of Clinical Endocrinology and The Obesity Society. He earned his medical degree with from the Royal College of Surgeons in Ireland, trained in Internal Medicine and Endocrinology at the Mayo Clinic, and completed a fellowship in Nutrition and Metabolic Diseases at UT Southwestern. Dr. Almandoz is an internationally recognized expert in comprehensive obesity care, with a focus on integrating nutrition and lifestyle, addressing health disparities, and long-term outcomes after bariatric surgery.
Accreditation Statement:
The Massachusetts Medical Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Massachusetts Medical Society designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Joint Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and the Massachusetts Medical Society. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Associates
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until November 18, 2026. PAs should only claim credit commensurate with the extent of their participation.
Nurses
Contact Hour(s): 1, of which x is eligible for pharmacology credit.
Available Credit
1.00 Participatio